Medtronic MiniMed Paradigm Veo Manuel d'utilisateur télécharger pdf (Page 16)

Medtronic Australasia Pty Ltd

Diabetes

97 Waterloo Road

North Ryde NSW 2113

Australia

Telephone: 02 9857 9000

Fax: 02 9857 9237

Tollfree: 1800 777 808

www.medtronic-diabetes.com.au

You should always seek advice from your medical

practitioner to determine your suitability for insulin

pump therapy. Use as directed.

Safety Information

Insulin Pump Therapy and Medtronic MiniMed Insulin Infusion Pumps

Patients should always discuss the benets and potential risks with a clinician. Please review the product’s technical manual prior to use for detailed

instructions and disclosure. Indications for use The insulin pump is indicated for the continuous delivery of insulin, at set and variable rates, for the

management of diabetes mellitus in persons requiring insulin. Contraindications Insulin pump therapy is not recommended for people who are

unwilling or unable to perform a minimum of four blood glucose tests per day and to maintain contact with their healthcare professional. While features

exist to help facilitate pump usage, Medtronic Diabetes does not recommend the use of this product by individuals whose impaired vision or hearing does

not allow full recognition of the pump signals and alarms.

Medtronic Diabetes Continuous Glucose Monitoring

Indications for use The CGM System is intended to continuously record interstitial glucose levels in persons with diabetes mellitus. This information is

intended to supplement, not replace, blood glucose information obtained using standard home glucose-monitoring devices. A conrmatory ngerstick

is required prior to treatment. This information collected by CGM may be downloaded and displayed on a computer and reviewed by you and your

healthcare professional. This information may allow identication of patterns of glucose-level excursions above or below the desired range, facilitating

therapy adjustments that may minimise these excursions. Contraindications Successful operation of CGM requires adequate vision and hearing. Use of

CGM is not recommended for patients whose impaired vision or hearing does not allow full recognition of the monitor signals and alarms, or who do not

have a caregiver who can perform this function for them.

1. The Diabetes Control and Complications Trial (DCCT) Research Group. The eect of intensive

treatment of diabetes on the development and progression of long-term complications in

insulin-dependent diabetes mellitus. NEJM. 1993;329(14):977-986.

2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions

and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and

cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353(25):2643-2653.

3. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes:

meta-analysis of multiple daily insulin injections compared with continuous subcutaneous

insulin infusion. Diab Med. 2008;25:765-774.

4. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1

diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-32.

5. Corriveau EA, et al. Eect of Carelink, an internet-based insulin pump monitoring system,

on glycemic control in rural and urban children with type 1 diabetes mellitus. Ped Diab.

2008;9(Part ii):360-366.

6. Hague C, Insulin Pumps - Evolution of an Industry, Business Brieng European

Pharmacotherapy. 2003:1-3.

Paradigm, Veo, Bolus Wizard, and MiniLink are trademarks and Medtronic CareLink is a

registered trademark of Medtronic MiniMed, Inc.

1 2 ... 11 12 13 14 15 16

Commentaires sur ces manuels

Pas de commentaire

Medtronic MiniMed Paradigm Veo Manuel d'utilisateur Page 16

Commentaires sur ces manuels

Produits connexes et manuels pour Non Medtronic MiniMed Paradigm Veo